AlphaYou
Overview
Key stats
Fundamentals Sep 10- Open
- $65.80
- 52-wk high
- $68.23
- High
- $68.23
- 52-wk low
- $22.05
- Low
- $65.59
- Prev close
- $66.07
- Mkt cap
- $6.23B
- Volume
- 1.24M
- Fwd P/E
- 43.5x
- Beta
- 1.06
- P/S
- 10.4x
- P/B
- 251.0x
- Profit margin
- -7.3%
- Op margin
- +2.3%
- ROE
- -236.4%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsSmart money
8 funds hold a position and insiders have been net selling.
What funds are doing
Earnings
Earnings came in $0.23 a share below what analysts expected.
Earnings per share
-$0.14 expected
Reports Oct 29, 2026, in 49 days
EPS expected
-$0.57 to $1.16
Revenue expected
13 analysts
Last 30 days
Analysts raising estimates
Estimate drift
Change in 30 days
Financials
What it sold, what it cost, what was left.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $164.9M | $129.7M | $127.2M | $169.6M |
| Cost of what it sold | $1.6M | $2.6M | $26.8M | $2.2M |
| Gross profit | $163.3M | $127.1M | $100.4M | $167.4M |
| What it spent | ||||
| Research and development | $51.9M | $57.9M | $57.1M | $60.3M |
| Sales and admin | $86.5M | $101.7M | $80.3M | $96.1M |
| Other operating costs | — | — | — | $7.1M |
| Total operating expenses | $138.3M | $159.6M | $137.3M | $163.5M |
| What was left | ||||
| Operating profit | $24.9M | -$32.4M | -$36.9M | $4.0M |
| Interest on debt | $2.8M | $2.3M | $2.3M | $2.1M |
| Profit before tax | $25.7M | -$21.1M | -$36.7M | -$35.0M |
| Tax | $8.0K | $921.0K | -$120.0K | -$204.0K |
| Net profit | $25.7M | $2.7M | -$37.1M | -$34.8M |
| EBITDA | $44.3M | -$632.0K | -$9.2M | -$32.9M |
Technicals
Price structure
This stock is in a strong uptrend.
Trend
Strong uptrend
100 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
News
What the news says
Coverage is bullish
Tone of tracked coverage
Travere Therapeutics stock hits 52-week high at 67.97 USD By Investing.com
BullishSep 4Travere Therapeutics CFO Christopher R. Cline Executes 642-Share Sale for Tax Withholding on RSU Vesting
NeutralSep 4Travere Therapeutics stock hits 52-week high at 67.97 USD By Investing.com
BullishSep 3Travere Therapeutics stock hits 52-week high at 67.97 USD By Investing.com
BullishSep 3
Macro
10 macro signals shaping TVTX right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results